NCT04620369
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must self report moderate nasal symptoms that began after the initiation chemotherapy including dryness, pain/discomfort, bleeding, scabbing, sores
Exclusions: Patients with previous exposure to rose geranium in sesame oil nasal spray
https://ClinicalTrials.gov/show/NCT04620369